Prostate Cancer

Sonablate HIFU Tissue Change Monitoring

HIFU, which stands for high intensity focused ultrasound is a recently approved new technology for prostate tissue ablation. Many urologists have worked with HIFU for several years to offer their patients a minimally invasive treatment option for prostate cancer, either as a part of a clinical trial or at international treatment centers outside the United States. There are currently two different medical devices that use HIFU energy to heat and destroy tissue in the prostate. The most technologically advanced HIFU device for prostate cancer is called the Sonablate. The Sonablate is a software directed device that includes a computer console, a transrectal probe and a chilling unit. The Sonablate software that physicians use to plan and execute Sonablate HIFU treatment has state-of-the-art features that make [...]

2017-12-13T13:37:21+00:00December 20th, 2016|

New study suggests a more accurate system for early detection, treatment of prostate cancer

A new study may lead to a more accurate system for early detection, diagnosis, and treatment of prostate cancer. It’s a promising development given prostate cancer is the second most common cancer among men worldwide, responsible for 308,000 deaths in 2012 and estimated to take 26,120 lives in the U.S. alone in 2016. New research coauthored by Brigham Young University researchers may lead to a more accurate system for early detection, diagnosis, and treatment of prostate cancer. The new study, published this week in Proceedings of the National Academy of Sciences, details a computer model that uses medical images to reproduce the growth patterns of prostate cancer on the anatomy of a patient's prostate. This type of mathematical modeling and simulation of disease (aka predictive [...]

2017-12-13T13:37:21+00:00December 6th, 2016|

One year following FDA approval California HIFU is Giving Prostate Cancer Patients Hope for a Healthy Future

Santa Rosa Urologist Dr. Michael Lazar celebrates California HIFU’s first anniversary with look back at October 2015 when HIFU received approval from Food and Drug Administration for use in the U.S. High-intensity focused ultrasound (HIFU) is a technology that targets cancer cells with precision in a one to four-hour procedure that has little or no side effects, provides a remarkably quick recovery rate, and gives men diagnosed with prostate cancer a less invasive option over surgery or radiation. “The oncological results for HIFU is comparable to more traditional prostate cancer treatments including radical surgery or radiation. But the side effects for HIFU patients have proven to be much less debilitating than more radical procedures,” says Dr. Lazar. “For example, if the HIFU procedure is performed [...]

2017-12-13T13:37:21+00:00November 22nd, 2016|

Researchers discover three novel intrinsic subtypes of prostate cancer

In the largest study of its kind to date, researchers have identified and validated three distinct molecular subtypes of prostate cancer that correlate with distant metastasis-free survival and can assist in future research to determine how patients will respond to treatment, according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO). Findings represent a step toward the implementation of personalized medicine in prostate cancer care. To diagnose and determine treatment for prostate cancer, clinicians consider many factors, including a digital rectal exam, the prostate specific antigen (PSA) level in a patient's blood and prostate tumor biopsy results. Molecular subtyping of tumor cells allows oncologists to individualize care and tailor treatment based on the actual biology of each patient's [...]

2017-12-13T13:37:21+00:00November 1st, 2016|

Researchers say genomic fingerprinting important for treating prostate cancer

While the majority of prostate cancers are slow growing and not fatal, some are aggressive and lethal. Genomic fingerprinting can help predict a tumor's aggressiveness and tailor treatment plans; however, in the majority of cases involving multiple prostate tumors, only the largest tumor is typically fingerprinted -- resulting in more aggressive tumors potentially going undetected. Writing in the journal European Urology, a research team led by Hannelore Heemers, Ph.D., of Cleveland Clinic's Lerner Research Institute Department of Cancer Biology, and James Mohler, M.D., chair of the Department of Urology at Roswell Park Cancer Institute in Buffalo, has demonstrated that when genomic fingerprinting is performed on only a single tumor sample, a smaller but more aggressive tumor could potentially be missed. The finding underscores the importance [...]

2017-12-13T13:37:21+00:00October 4th, 2016|

New trial results encourage patients to weigh long-term impact of treatment options with their doctors

(Published on ScienceDaily - September 15, 2016) In light of the findings from the Prostate Testing for Cancer and Treatment (ProtecT) trial published in the New England Journal of Medicine, the American Society for Radiation Oncology (ASTRO) would like to congratulate the authors and investigators for conceiving and completing a difficult clinical trial to randomize care for 2,664 men who volunteered to be a part of this study. Their paper emphasizes the importance of joint decision making between prostate cancer patients and their physicians when weighing treatment options for early stage disease. Findings from the ProtecT trial can help patients understand the full range of approaches to manage their disease, including the risks and benefits of active monitoring versus early treatment with radiation therapy (RT) [...]

2017-12-13T13:37:22+00:00September 20th, 2016|

Obesity and a high-fat diet promote prostate cancer progression

Metabolites from a fatty diet join forces with the cancer-driving gene MYC to reprogram prostate cancer cells to grow faster, finds new study. This discovery solidifies a direct link between obesity and lethal prostate cancer. At the 2016 Annual American Association for Cancer Research (AACR) Conference, Giorgia Zadra, PhD, of the Harvard: Dana-Farber Cancer Institute and Brigham and Women's Hospital, presented results from a study that helped to clarify the relationship between obesity and prostate cancer. The skinny? Fat increases the activity of a critical cancer-driving gene called MYC. Cancer is a greedy disease. Tumors plunder the body's resources - vitamins and nutrients, energy and oxygen, and vital space as tumors grow to ultimately cause lethal damage. Worst of all, cancer steals precious time away [...]

2017-12-13T13:37:22+00:00July 5th, 2016|

Mayo Clinic: Tips on Prostate cancer prevention

There's no proven prostate cancer prevention strategy. But one way to reduce the risk of prostate cancer is by making healthy choices, such as exercising and eating a healthy diet. Study results often conflict with each other and most studies aren't designed to definitively prove whether something prevents prostate cancer. As a result, no clear ways to prevent prostate cancer have emerged. In general, doctors recommend that men with an average risk of prostate cancer make choices that benefit their overall health if they're interested in prostate cancer prevention. Choose a healthy diet There is some evidence that choosing a healthy diet that's low in fat and full of fruits and vegetables may contribute to a lower risk of prostate cancer, though this hasn't been [...]

2017-12-13T13:37:22+00:00June 28th, 2016|

New Study: PSA levels in younger men might predict future risk of prostate cancer

Prostate cancer screening with prostate-specific antigen (PSA) has been shown to reduce death and the spread of prostate cancer to other parts of the body, but the PSA test remains highly controversial as it frequently leads to over diagnosis and over treatment of men who may not be at risk. Smarter screening strategies that can improve the accuracy of diagnosing lethal prostate cancer are urgently needed. Through a prospective study of US men, investigators from Brigham and Women's Hospital and the Harvard T.H. Chan School of Public Health have found that measuring PSA levels in younger men (between the ages of 40 and 59) could accurately predict future risk of lethal prostate cancer later in life. Their findings suggest that screening PSA levels in men [...]

2017-12-13T13:37:22+00:00June 21st, 2016|

California HIFU and Dr. Michael Lazar Recognizes Men’s Health Month With a Look at Prostate Cancer

California HIFU and Dr. Michael Lazar are helping to recognize Men’s Health Month by providing some valuable information and resources for men on Prostate Cancer. The idea behind Men's Health Month is to heighten the awareness of preventable health problems like prostate cancer, and to encourage early detection and treatment. Dr. Lazar and his staff are proud to be early leaders in the usage of HIFU, a medical procedure that applies high-intensity focused ultrasound energy to locally heat and destroy diseased or damaged tissue with prostate cancer through ablation. Informed Decision Making According to The Center for Disease Control and Prevention (CDC) it is important for men to be aware of prostate cancer risks and to make informed decisions. This happens best when a man— [...]

2017-12-13T13:37:22+00:00June 14th, 2016|